Today: 2 February 2026
Subscribe
Browse Category

Biotechnology News 6 January 2026 - 8 January 2026

MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials

MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials

New York, Jan 8, 2026, 17:06 EST — After-hours MoonLake Immunotherapeutics shares jumped 27% to $14.34 on Thursday after the biotech said U.S. regulators supported a route to file its hidradenitis suppurativa treatment without doing more trials for the skin disease. The stock churned between $11.20 and $17.28, and roughly 24 million shares traded. The update is a big deal…
8 January 2026
·····
Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

Merck stock climbs on Wolfe upgrade as Cidara deal closes and Gardasil questions linger

New York, Jan 8, 2026, 13:46 EST — Regular session Merck & Co shares rose 1.5% to $110.20 in afternoon trading on Thursday after Wolfe Research upgraded the drugmaker, outpacing a softer health-care sector. The stock traded as high as $112.08 and as low as $107.94, while AbbVie slid about 3.9% and the S&P 500 ETF was little changed. The…
8 January 2026
······
Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

Immuneering (IMRX) stock jumps in premarket after 12-month pancreatic cancer survival update

NEW YORK, Jan 8, 2026, 08:39 EST — Premarket Shares of Immuneering Corp jumped about 24% to $8.33 in premarket trading on Thursday, after the biotech released updated survival data for its lead pancreatic cancer program. The stock last closed at $6.74. The update matters because Immuneering’s valuation hinges on whether atebimetinib can hold up as the company pushes toward…
8 January 2026
·····
Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

Amgen stock jumps on UBS buy call as Dark Blue deal sharpens focus on pipeline

NEW YORK, January 7, 2026, 19:17 EST — After-hours Amgen shares (AMGN.O) rose 3.5% to $341.64 in Wednesday’s regular session and were last near that level after the bell. UBS assumed coverage with a buy rating and a $380 price target, saying it sees “upside from EPS and pipeline.” Why this matters now is simple: investors are testing whether Amgen’s…
8 January 2026
······
Thermo Fisher stock slips after-hours as TD Cowen lifts target ahead of JPM talk, earnings

Thermo Fisher stock slips after-hours as TD Cowen lifts target ahead of JPM talk, earnings

New York, Jan 7, 2026, 18:54 EST — After-hours Thermo Fisher Scientific shares slipped about 0.6% in after-hours trading on Wednesday to $617.15, after swinging between $611.93 and $626.40 during the session. The dip comes with the stock sitting near recent highs and the calendar tightening. Investors are staring at next week’s J.P. Morgan Healthcare Conference and Thermo Fisher’s quarterly…
8 January 2026
·····
Viasat stock slides as Evergreen signs on for Inmarsat NexusWave, CFO sale hits tape

Viasat stock slides as Evergreen signs on for Inmarsat NexusWave, CFO sale hits tape

New York, January 7, 2026, 13:26 EST — Regular session Viasat shares fell $4.89, or about 11.3%, to $38.57 on Wednesday, a day after the stock closed at $43.46. The shares traded between $38.27 and $43.58. The drop comes as investors weigh whether Viasat’s Inmarsat business can keep landing big mobility customers that buy recurring service, not just hardware. Maritime…
7 January 2026
·····
Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

Why Wave Life Sciences (WVE) stock is up today after Arrowhead’s obesity data spotlights INHBE

New York, Jan 7, 2026, 12:57 (EST) — Regular session Wave Life Sciences shares rose 4.4% to $15.82 in midday trade on Wednesday. The stock has stayed in motion as investors circle back to obesity plays tied to a gene target called INHBE. The spark this week came from Arrowhead Pharmaceuticals, which on Tuesday posted interim results from its obesity…
7 January 2026
·····
Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

New York, January 7, 2026, 12:25 (EST) — Regular session Shares of Adaptive Biotechnologies rose 6.5% to $17.15 on Wednesday, after trading between $16.24 and $17.33, giving the company a market value of about $2.0 billion. The stock has traded between $4.32 and $21.89 over the past 52 weeks. The move matters now because investors have been bidding up riskier…
7 January 2026
·····
Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

Structure Therapeutics stock climbs on $100 million Roche-Genentech patent deal; what investors watch next

New York, Jan 7, 2026, 11:50 a.m. EST — Regular session Shares of Structure Therapeutics Inc rose 5.6% to $66.75 in late-morning trade on Wednesday, recovering from early swings as investors sized up a newly disclosed patent license deal tied to Roche and Genentech’s oral obesity drug effort. The agreement matters because it puts near-term cash on the table for…
7 January 2026
···
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk

New York, January 7, 2026, 09:54 EST — Regular session Pfizer shares rose about 0.9% to $25.67 in morning trade on Wednesday, even as investors weighed a new patent lawsuit tied to its COVID-19 vaccine and a cautious call from UBS. UBS began coverage of Pfizer with a Neutral rating and a $25 price target, pointing to what it described…
7 January 2026
······
Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

Regencell Bioscience (RGC) stock jumps again: what to know behind the latest sharp swing

New York, Jan 6, 2026, 12:38 (EST) — Regular session Regencell Bioscience Holdings Ltd shares rose 18.3% to $31.99 on Tuesday, after touching $34.40 earlier and sliding as low as $26.60. The Nasdaq-listed stock was last up $4.95 from Monday’s close of $27.04, with about 850,000 shares traded. The move keeps the Hong Kong-based bioscience company on momentum traders’ radar…
6 January 2026
·····
1 … 4 5 6 7 8 … 24

Stock Market Today

  • Teacher Retirement System of Texas Boosts Pfizer Holdings by 32.3% in Q3
    February 2, 2026, 10:44 AM EST. Teacher Retirement System of Texas increased its Pfizer Inc. (NYSE:PFE) shares by 32.3%, acquiring 675,419 shares to hold 2.76 million shares worth $70.43 million at quarter-end. Other investors like Brighton Jones LLC and Revolve Wealth Partners also raised stakes. Pfizer reported quarterly earnings of $0.87 per share, surpassing estimates by $0.08, with net margin at 15.65%. Revenue stood at $16.65 billion, slightly below expectations. The company projects 2025 earnings per share between $3.00 and $3.15. Pfizer's stock recently traded near a 52-week high of $27.69 with a market cap of $148.34 billion. Institutional investors hold 68.36% of shares, reflecting strong confidence amid mixed earnings and moderate revenue performance.
Go toTop